Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer

Sponsor
Hellenic Oncology Research Group
Study ID
NCT00741195
Phase
PHASE2
Status
Completed

Conditions

  • Non-small-cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Docetaxel — DRUG
    Docetaxel at the dose of 75 mg/m2 IV on days 1 every 3 weeks for 6 consecutive cycles.
  • Bevacizumab — DRUG
    Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles

Study Details

This trial will evaluate the efficacy and safety of docetaxel plus bevacizumab in patients with pretreated, advanced non small cell lung cancer (NSCLC).

Key Dates

First listed
Aug 26, 2008
Start date
Apr 30, 2008
Status verified
Oct 2016
Primary completion
Oct 31, 2016
Completion
Oct 31, 2016

Study Design

Enrollment
50 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    Docetaxel/Bevacizumab

Primary Outcome Measure

Progression Free Survival [ Time Frame: 1 year ]

Related Studies